Vivek Subbiah/LinkedIn
Jul 13, 2025, 13:33
Vivek Subbiah: Essential Tools Toward More Globally Inclusive and Data-Driven Drug Development
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“The ability to model outcomes for patient groups who wouldn’t typically be included in clinical trials is not just a technical achievement-it’s a clinical and strategic one.
It opens the door to faster trial design, smarter expansion decisions, and better evidence for patients who are often overlooked.
These kinds of tools will be essential as we push toward more globally inclusive and data-driven drug development.”
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 13, 2025, 13:25
Jul 13, 2025, 13:20
Jul 13, 2025, 12:56
Jul 13, 2025, 12:41
Jul 13, 2025, 12:32